Sherene Loi, MD

This account is verified. Learn more

@LoiSher

Professor, Medical Oncologist #LoiLab @PeterMacCC @UniMelb @NBCFAus, #IBSCGchair @etop_ibcsg, @TILsWorkgroup cofounder; coEditor-in-Chief @esmo_iotech own views

Melbourne, Australia petermac.org/research/labs/… Joined August 2011

912 Following 4.4K Followers 1K Posts

Latest posts 5

Pinned post

Sherene Loi, MD @LoiSher Jul 6, 2024

Our latest review is out now on targeting #BreastCancer #Immunity #tme #trm #CancerResearch many thanks to @NatureRevCancer

@PeterMacCC @PeterMacRes @TILsWorkGroup

Nature Reviews Cancer @NatureRevCancer Jul 5, 2024

Towards targeting the breast cancer immune microenvironment dlvr.it/T9C7GF
View quoted post on X

Sherene Loi, MD @LoiSher Oct 26

Excellent rapid oral session 2 in #advancedbreastcancer today
New advances in #ADC, #CNS treatment in #HER2 #BreastCancer #ESMO26 #ESMOAmbassadors

ESMO - Eur. Oncology Verified account @myESMO Oct 26

#ESMO26: Practice-changing improvement in intracranial progression-free survival seen with the addition of tucatinib to standard therapy in HER2-positive metastatic #BreastCancer (#MBC) in the BRIDGET #ClinicalTrial.
Read more ow.ly/Gc4550ZZO6K

#InsightsbyESMO

View quoted post on X

Sherene Loi, MD @LoiSher Oct 25

#keynoteB49- @myESMO #ESMO26
Adding ICB/ immunotherapy in advanced HR+ #breastcancer - wishful thinking 🤔 this context is immune deplete! -PFS 6-6.7 mo

➡️ Early high grade immune + HR + BC is the right place for it
#ESMOAmbassadors

ESMO - Eur. Oncology Verified account @myESMO Oct 24

#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49

🔗 ow.ly/5NoZ50ZZjCH

#ClinicalTrial #BreastCancer #InsightsbyESMO
@PTarantinoMD

View quoted post on X

Sherene Loi, MD @LoiSher Oct 24

#ESMO2026
PostMonarch - change to Fulvestrant v placebo with Abema- continues to show better PFS and OS
➡️ results by ESR1 status eagerly awaited!
#ESMOAmbassadors @OncoAlert
Published online in @Annals_Oncology

Sherene Loi, MD @LoiSher Oct 23

🎉The only agent that can really increase pCR in a subset of early HR+ #BreastCancer is #ICB
#ESMO2026 #ESMOAmbassadors

ESMO - Eur. Oncology Verified account @myESMO Oct 23

#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO
➡️ ow.ly/ZBwi50ZZXLm

View quoted post on X